ProQR Therapeutics N.V. Forecast, price target & analysts
ProQR Therapeutics N.V. Target price 2024 - Analyst rating & recommendation
ProQR Therapeutics N.V. Classifications & Recommendation:
ProQR Therapeutics N.V. Target price
| Target price | $4.28 |
| Course | $1.65 |
| Price potential |
159.46%
register free of charge
|
| Number of estimates | 6 |
|
6 Analysts have issued a price target ProQR Therapeutics N.V. 2025 .
The average ProQR Therapeutics N.V. target price is $4.28.
This is
159.46%
register free of charge
$6.05
266.41%
register free of charge
$2.00
21.49%
register free of charge
|
|
| A rating was issued by 6 analysts: 5 Analysts recommend ProQR Therapeutics N.V. to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst estimates: Analysts believe that the ProQR Therapeutics N.V. share has an average upside potential 2025 of
159.46%
register free of charge
|
Sales and margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Turnover Million $ | 7.04 | 23.67 |
| 66.04% | 236.28% | |
| EBITDA margin | -496.88% | -238.20% |
| 68.16% | 52.06% | |
| Net margin | -440.78% | -114.91% |
| 76.16% | 73.93% |
5 Analysts have issued a sales forecast ProQR Therapeutics N.V. 2024 . The average ProQR Therapeutics N.V. sales estimate is
This results in the following potential growth figures:
1 Analyst has issued an EBITDA forecast ProQR Therapeutics N.V. 2024 . The average ProQR Therapeutics N.V. EBITDA estimate is
This results in the following potential growth figures and future EBITDA margins:
1 Analyst has issued a net profit forecast ProQR Therapeutics N.V. 2024 . The average ProQR Therapeutics N.V. net profit estimate is
This results in the following potential growth figures and future net margins:
Earnings per share, P/E ratio and EV/sales forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Earnings per share $ | -0.38 | -0.33 |
| 60.42% | 13.16% | |
| P/E ratio | negative | |
| EV/Sales | 1.82 |
1 Analysts have issued a ProQR Therapeutics N.V. forecast for earnings per share. The average ProQR Therapeutics N.V. <a href=/blog/eps>EPS is
This results in the following potential growth figures and future valuations:
Based on analysts' sales estimates for 2024, the ProQR Therapeutics N.V. share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of
This results in the following potential growth figures and future valuations:
ProQR Therapeutics N.V....
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
